Aura Biosciences, Inc.
NASDAQ:AURABiotechnology
-$0.09 today
- Market cap
- $743.09M
- Beta
- 0.39
- P/E (TTM)
- -3.7
- EPS (TTM)
- -$1.67
Volume 0.69M
Average 0.52M
AURA Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Aura Biosciences, Inc.NASDAQ: AURA
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $274K fell 5.8% year over year, ahead of the -6.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.7% from the prior quarter. Over 3 fiscal years it compounded at -1.4% a year.
Context
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -5.8% holds above the trailing-twelve-month pace of -6.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 1.13M USD
- Year-over-year change
- -7.7%
- 4-year CAGR
- +8.0%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.13M | -7.7% |
| FY2024 | 2024-12-31 | 1.22M | -5.6% |
| FY2023 | 2023-12-31 | 1.3M | +10.0% |
| FY2022 | 2022-12-31 | 1.18M | +41.6% |
| FY2021 | 2021-12-31 | 831K | — |
Depreciation & Amortization vs competitors
How AURA compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -6.8% is the 6th highest of 11, against a peer median of -6.2%.
- Over three fiscal years its annual growth of -1.4% compares with a peer median of +9.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.09M USD | -5.1% | -15.4% | 4.5% | |
| LTM Mar 2026 | $5.92M USD | -17.6% | +20.3% | 9.3% | |
| LTM Sep 2026 | $2.69M USD | -3.0% | +67.3% | — | |
| LTM Mar 2026 | $2.47M USD | -8.6% | +70.7% | 55.3% | |
| LTM Mar 2026 | $2.45M USD | +41.2% | -1.9% | 32.1% | |
| FY2025 | $2.33M USD | +47.9% | +73.6% | 35.8% | |
| LTM Mar 2026 | $1.13M USD | -6.8% | -1.4% | — | |
| LTM Mar 2026 | CHF 422.43K CHF | -7.4% | +20.4% | 83.8% | |
| LTM Mar 2026 | $248K USD | -57.2% | -46.1% | — | |
| LTM Mar 2026 | $119.64K USD | +3.7% | -17.0% | 35.9% | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | $22K USD | -88.5% | -20.8% | — |
| Peer median (excluding AURA) | — | -6.2% | +9.2% | 35.8% | |
Competitors are the stored peer set for AURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 1.3M | 0 | 0 |
| Gross Profit | 0 | 0 | (1.3M) | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 25.16M | 42.24M | 63.94M | 73.3M | 90.3M |
| Selling, General & Admin | 10.09M | 18.06M | 19.76M | 22.81M | 22.49M |
| Operating Expenses | 35.25M | 60.3M | 83.7M | 96.12M | 112.79M |
| Depreciation & Amortization | 831K | 1.18M | 1.3M | 1.22M | 1.13M |
| EBITDA | (34.41M) | (57.59M) | (74.98M) | (85.58M) | (104.95M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (35.25M) | (60.3M) | (84.99M) | (96.12M) | (112.79M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 13K | 1.86M | 8.59M | 9.43M | 6.63M |
| Interest Expense | 13K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (1K) | 1.53M | 8.72M | 9.31M | 6.71M |
| Income Before Tax | (35.25M) | (58.76M) | (76.27M) | (86.81M) | (106.08M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 137K | 112K | 108K |
| Net Income | (35.25M) | (58.76M) | (76.41M) | (86.92M) | (106.19M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.58) | (1.96) | (1.93) | (1.75) | (1.76) |
| EPS (Diluted) | (1.58) | (1.96) | (1.93) | (1.75) | (1.76) |
| Weighted Avg Shares | 29.21M | 29.94M | 39.62M | 49.65M | 60.34M |
| Weighted Avg Shares (Diluted) | 29.21M | 29.94M | 39.62M | 49.65M | 60.34M |
Aura Biosciences, Inc.
NASDAQ:AURA
Intrinsic Alpha fair value
Locked
Current Price
$7.14
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.